Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1996 1
1998 1
2002 1
2005 1
2006 1
2007 1
2008 1
2009 3
2011 5
2014 2
2015 7
2016 4
2017 8
2018 7
2019 6
2020 5
2021 9
2022 6
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

64 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "EGFR NP_005219.2:p.G719fs*29"
Page 1
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY, Bischoff HG, Peled N, Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC, Garassino MC; KEYNOTE-189 Investigators. Gandhi L, et al. N Engl J Med. 2018 May 31;378(22):2078-2092. doi: 10.1056/NEJMoa1801005. Epub 2018 Apr 16. N Engl J Med. 2018. PMID: 29658856 Free article. Clinical Trial.
BACKGROUND: First-line therapy for advanced non-small-cell lung cancer (NSCLC) that lacks targetable mutations is platinum-based chemotherapy. Among patients with a tumor proportion score for programmed death ligand 1 (PD-L1) of 50% or greater, pembrolizumab has replaced c …
BACKGROUND: First-line therapy for advanced non-small-cell lung cancer (NSCLC) that lacks targetable mutations is platinum-based chemotherap …
Tracking the Evolution of Non-Small-Cell Lung Cancer.
Jamal-Hanjani M, Wilson GA, McGranahan N, Birkbak NJ, Watkins TBK, Veeriah S, Shafi S, Johnson DH, Mitter R, Rosenthal R, Salm M, Horswell S, Escudero M, Matthews N, Rowan A, Chambers T, Moore DA, Turajlic S, Xu H, Lee SM, Forster MD, Ahmad T, Hiley CT, Abbosh C, Falzon M, Borg E, Marafioti T, Lawrence D, Hayward M, Kolvekar S, Panagiotopoulos N, Janes SM, Thakrar R, Ahmed A, Blackhall F, Summers Y, Shah R, Joseph L, Quinn AM, Crosbie PA, Naidu B, Middleton G, Langman G, Trotter S, Nicolson M, Remmen H, Kerr K, Chetty M, Gomersall L, Fennell DA, Nakas A, Rathinam S, Anand G, Khan S, Russell P, Ezhil V, Ismail B, Irvin-Sellers M, Prakash V, Lester JF, Kornaszewska M, Attanoos R, Adams H, Davies H, Dentro S, Taniere P, O'Sullivan B, Lowe HL, Hartley JA, Iles N, Bell H, Ngai Y, Shaw JA, Herrero J, Szallasi Z, Schwarz RF, Stewart A, Quezada SA, Le Quesne J, Van Loo P, Dive C, Hackshaw A, Swanton C; TRACERx Consortium. Jamal-Hanjani M, et al. N Engl J Med. 2017 Jun 1;376(22):2109-2121. doi: 10.1056/NEJMoa1616288. Epub 2017 Apr 26. N Engl J Med. 2017. PMID: 28445112 Free article.
We sequenced and analyzed 327 tumor regions to define evolutionary histories, obtain a census of clonal and subclonal events, and assess the relationship between intratumor heterogeneity and recurrence-free survival. RESULTS: We observed widespread intratumor heterogeneity …
We sequenced and analyzed 327 tumor regions to define evolutionary histories, obtain a census of clonal and subclonal events, and assess the …
Renal Allograft Dysfunction: Evaluation with Shear-wave Sonoelastography.
Ghonge NP, Mohan M, Kashyap V, Jasuja S. Ghonge NP, et al. Radiology. 2018 Jul;288(1):146-152. doi: 10.1148/radiol.2018170577. Epub 2018 Apr 10. Radiology. 2018. PMID: 29634441
Purpose To evaluate whether shear-wave sonoelastography can help differentiate stable renal allograft from acute allograft dysfunction and chronic allograft dysfunction and to correlate shear-wave sonoelastography measurements with resistive index (RI), serum creatinine level, es …
Purpose To evaluate whether shear-wave sonoelastography can help differentiate stable renal allograft from acute allograft dysfunction and c …
Circulating suPAR associates with severity and in-hospital progression of COVID-19.
Chalkias A, Skoulakis A, Papagiannakis N, Laou E, Tourlakopoulos K, Pagonis A, Michou A, Ntalarizou N, Mermiri M, Ragias D, Bernal-Morell E, Cebreiros López I, García de Guadiana-Romualdo L, Eugen-Olsen J, Gourgoulianis K, Pantazopoulos I; SPARCOL Investigators. Chalkias A, et al. Eur J Clin Invest. 2022 Jul;52(7):e13794. doi: 10.1111/eci.13794. Epub 2022 May 4. Eur J Clin Invest. 2022. PMID: 35435245 Free PMC article.
The aim of this study was to assess whether suPAR and other markers measured at hospital admission can predict the severity of COVID-19. METHODS: The primary outcome measure in this international, multi-centre, prospective, observational study with adult patients ho …
The aim of this study was to assess whether suPAR and other markers measured at hospital admission can predict the severity of COVID- …
Comparative Study to Evaluate the Effect of Low-Protein Diet Supplementation with Taurine and N-Acetylcysteine, N-Acetylcysteine and Pyridoxamine Dihydrochloride in Preventing the Progression of Chronic Renal Failure in Patients with Non-Diabetic Kidney Disease.
Sengupta P, Biswas S, Roy T. Sengupta P, et al. J Assoc Physicians India. 2022 May;70(5):11-12. J Assoc Physicians India. 2022. PMID: 35598122 Clinical Trial.
In the subgroup analysis a significant effect was observed in the cases of patients receiving NP with baseline eGFR more than 45 ml/min. The mean increase in eGFR readings over six months was 8.15 units higher in the NP group than in the control …
In the subgroup analysis a significant effect was observed in the cases of patients receiving NP with baseline eGFR mor …
A novel kidney disease index reflecting both the albumin-to-creatinine ratio and estimated glomerular filtration rate, predicted cardiovascular and kidney outcomes in type 2 diabetes.
Gerstein HC, Ramasundarahettige C, Avezum A, Basile J, Conget I, Cushman WC, Dagenais GR, Franek E, Lakshmanan M, Lanas F, Leiter LA, Pogosova N, Probstfield J, Raubenheimer PJ, Riddle M, Shaw J, Sheu WH, Temelkova-Kurktschiev T, Turfanda I, Xavier D. Gerstein HC, et al. Cardiovasc Diabetol. 2022 Aug 22;21(1):158. doi: 10.1186/s12933-022-01594-6. Cardiovasc Diabetol. 2022. PMID: 35996147 Free PMC article. Clinical Trial.
BACKGROUND: The estimated glomerular filtration rate (eGFR) and the albumin-to-creatinine ratio (ACR) are risk factors for diabetes-related outcomes. ...The hazard of the geometric mean of these two baseline measures (the kidney disease index or KDI) was also assessed. RES …
BACKGROUND: The estimated glomerular filtration rate (eGFR) and the albumin-to-creatinine ratio (ACR) are risk factors for diabetes-r …
Circulating levels of asprosin and its association with insulin resistance and renal function in patients with type 2 diabetes mellitus and diabetic nephropathy.
Goodarzi G, Setayesh L, Fadaei R, Khamseh ME, Aliakbari F, Hosseini J, Moradi N. Goodarzi G, et al. Mol Biol Rep. 2021 Jul;48(7):5443-5450. doi: 10.1007/s11033-021-06551-2. Epub 2021 Jul 25. Mol Biol Rep. 2021. PMID: 34304366
METHODS: Serum levels of asprosin, adiponectin, IL-6, and TNF-alpha were measured in 55 control subjects, 54 T2DM, and 55 T2DM + NP patients using ELISA kits. RESULTS: Asprosin was found to be higher in the T2DM (6.73 1.67) and T2DM + NP (7.11 1.54) patients compare …
METHODS: Serum levels of asprosin, adiponectin, IL-6, and TNF-alpha were measured in 55 control subjects, 54 T2DM, and 55 T2DM + NP p …
Histo-Molecular Factors of Response to Combined Chemotherapy and Immunotherapy in Non-Small Cell Lung Cancers.
Marchal M, Leroy V, Behal H, Dansin E, Paris N, Bordier S, Humez S, Escande F, Gauvain C, Cortot AB. Marchal M, et al. Target Oncol. 2023 Nov;18(6):927-939. doi: 10.1007/s11523-023-01009-w. Epub 2023 Nov 3. Target Oncol. 2023. PMID: 37921939 Free PMC article.
Per subgroup, the median PFS was 7.1 months (5.4-8.9) for KRAS, 5.5 months (2.5-15.3) for EGFR/ALK/ROS1/RET, 12.9 months (2.6-not reached [NR]) for BRAF, 1.5 months (0.6-NR) for MET, 3.9 months (2.6-NR) for HER2, and 5.6 months (4.7-7.8) for patients without any oncogenic …
Per subgroup, the median PFS was 7.1 months (5.4-8.9) for KRAS, 5.5 months (2.5-15.3) for EGFR/ALK/ROS1/RET, 12.9 months (2.6-not rea …
Alysicarpus vaginalis Bio-Actives as ESR Signaling Pathway Inhibitor for Breast Cancer Treatment: A Network Pharmacology Approach.
Sakle NS, More SA, Mokale SN. Sakle NS, et al. Nutr Cancer. 2022;74(6):2222-2234. doi: 10.1080/01635581.2021.1986080. Epub 2021 Oct 6. Nutr Cancer. 2022. PMID: 34612094
GO and KEGG enrichment analysis predicted the ERR, c-MET, PDGFR-alpha/beta, EGFR, and VEGF as a key targets in the breast cancer treatment which are validated via molecular modeling. Expression of ER-alpha, AR and EGFR were significantly down regulated by AV …
GO and KEGG enrichment analysis predicted the ERR, c-MET, PDGFR-alpha/beta, EGFR, and VEGF as a key targets in the breast canc …
Clinical and diagnostic findings in COVID-19 patients: an original research from SG Moscati Hospital in Taranto Italy.
Balzanelli M, Distratis P, Catucci O, Amatulli F, Cefalo A, Lazzaro R, Aityan KS, Dalagni G, Nico A, De Michele A, Mazza E, Tampoia M, D'Errico P, Pricolo G, Prudenzano A, D'Ettorre E, Di Stasi C, Morrone LFP, Nguyen KCD, Pham HV, Inchingolo F, Tomassone D, Gargiulo Isacco C. Balzanelli M, et al. J Biol Regul Homeost Agents. 2021 Jan-Feb;35(1):171-183. doi: 10.23812/20-605-A. J Biol Regul Homeost Agents. 2021. PMID: 33491346
Patients were divided into four groups, positive-positive (ER-PP), negative-positive (ER-NP), negative-negative (ER-NN) and a group admitted to the ICU (ER-IC). ...Fundamental differences were reported among the groups. Males were significantly higher in PP, ICU, and NP …
Patients were divided into four groups, positive-positive (ER-PP), negative-positive (ER-NP), negative-negative (ER-NN) and a group a …
64 results